Edmond de Rothschild Investment Partners, a France-based private equity firm, announced it is seeking investing in biotechnology companies in Spain, reported El Economista on 28 September 2016, citing Asebio Managing Director Ion Arocena.

Specifically, the Spanish Association of Bioenterprises (Asebio) noted Edmond de Rothschild Investment Partners, which manages assets worth EUR 150bn in ten areas of business, will meet with 23 Spain-based companies present at the congress held by Asebio.

Along with Edmond de Rothschild, another 45 local and international investment funds will participate in the event, such as Forbion, a Netherlands-based private equity firm, and other Spain-based private equity firms, such as Ysios Capital Partners, Caixa Capital Risc, and Cross Road Biotech, among others.

(content in spanish)

Edmond de Rothschild Investment Partners, firma de private equity con sede en Francia, ha anunciado que busca invertir en empresas de biotecnología en España, según ha informado El Economista el 28 de spetiembre de 2016, citando al director general de Asebio, Ion Arocena.

En concreto, la Asociación Española de Bioempresas (Asebio) ha informado que Edmond de Rothschild Investment Partners, que gestiona activos valorados en EUR 150.000m en diez áreas de negocio, tendrá reuniones con 23 empresas españolas presentes en el congreso organizado por Asebio.

Junto a Edmond de Rothschild, también participarán otros 45 fondos de inversión nacionales e internacionales, como Forbion, firma holandesa de private equity, y firmas españolas de private equity, como Ysios Capital Partners, Caixa Capital Risc y Cross Road Biotech, entre otros.